Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

897 Pre-clinical characterization of PEC3001, a PD-1 targeted IL-2Rα-active IL-2 immunocytokine with potent anti-tumor activity and a favorable safety profile

  • Kuan-Chun Huang1
  • Robert Wheeler2
  • Lih-Ling Lin3
  • Celesztina Nagy-Domonkos4
  • Ali Sepahi1
  • Molly Foster1
  • Kelsey Joyce1
  • Henry S Cheng1
  • Mei-Ling Yang1
  • Jack D Huck4
  • Pratiksha Ramteke1
  • Ming-Tang Chen1
8 more authors
  • Tom Lin1
  • Erik R Sampson1
  • Menqrong Wu5
  • Luke Lin5
  • Yite Yo5
  • Josephine Orrick4
  • Prasanna Baskar4
  • Shihlong Yan5
5 affiliations
  1. 1PharmaEssentia Innovation Research Center (PIRC), Bedford, MA, USA
  2. 2Paediatric Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK
  3. 3Inflammation and Immunology, Pfizer Research, 200 CambridgePark Drive, Cambridge, UK
  4. 4PharmaEssentia Innovation Research Center, Bedford, MA, USA
  5. 5PharmaEssentia Corporation, Taipei, Taiwan
Open at sourcePDFDOICite

Related

  1. Cross-Cancer Characterization of CAMK2A Reveals Its Favorable Prognostic Association and Neuronal Signature Enrichment in Glioma.
    Yimin Pan, Changwu Wu, Jun Tan +2
    BiomedicinesPeer-reviewedCC BYFull textHuman geneticsEurope PMC
  2. Intranasal CBT101 demonstrates favorable safety and neurophysiological evidence of central activity in healthy male volunteers
    Henri Benech, Lila Krebs-Drouot, Geoffrey Viardot +7
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textNeurologyCrossrefPMC
  3. 811 AR166, a novel tri-specific immunocytokine, overcomes anti-PD-1 resistance by delivering cis-acting IL-2v via dual PD-1 and LAG-3 targeting
    Su-Hyung Park, Wooick Jang, Jinkeol Mok +15
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. Immune-related adverse events are associated with favorable clinical outcomes in esophageal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Jiajia Fan, Dongmei Chen, Liqun Jia
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  5. Extracellular matrix–targeted TNC-scFv armoring enhances CAR T cell persistence and antitumor activity in solid tumors
    Kaizhao Chen, Qi Fu, Wei Zhang +11
    Science AdvancesPeer-reviewedCC BY-NCOncologyCrossref

Cite

BibTeXRIS
BibTeX
@article{huang2026preclinical,
  title = {{897 Pre-clinical characterization of PEC3001, a PD-1 targeted IL-2Rα-active IL-2 immunocytokine with potent anti-tumor activity and a favorable safety profile}},
  author = {Kuan-Chun Huang and Robert Wheeler and Lih-Ling Lin and Celesztina Nagy-Domonkos and Ali Sepahi and Molly Foster and Kelsey Joyce and Henry S Cheng and Mei-Ling Yang and Jack D Huck and Pratiksha Ramteke and Ming-Tang Chen and Tom Lin and Erik R Sampson and Menqrong Wu and Luke Lin and Yite Yo and Josephine Orrick and Prasanna Baskar and Shihlong Yan},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0897},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0897},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 897 Pre-clinical characterization of PEC3001, a PD-1 targeted IL-2Rα-active IL-2 immunocytokine with potent anti-tumor activity and a favorable safety profile
AU  - Kuan-Chun Huang
AU  - Robert Wheeler
AU  - Lih-Ling Lin
AU  - Celesztina Nagy-Domonkos
AU  - Ali Sepahi
AU  - Molly Foster
AU  - Kelsey Joyce
AU  - Henry S Cheng
AU  - Mei-Ling Yang
AU  - Jack D Huck
AU  - Pratiksha Ramteke
AU  - Ming-Tang Chen
AU  - Tom Lin
AU  - Erik R Sampson
AU  - Menqrong Wu
AU  - Luke Lin
AU  - Yite Yo
AU  - Josephine Orrick
AU  - Prasanna Baskar
AU  - Shihlong Yan
PY  - 2026
DA  - 2026/11/07
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0897
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0897
SN  - 2051-1426
ER  -